Description

Tipifarnib is a potent and selective farnesyltransferase inhibitor, representing a significant class of targeted therapeutic agents. Its primary value lies in its ability to interfere with the post-translational modification of proteins like Ras, which is crucial in the signaling pathways of various cancers. This compound is essential for pharmaceutical R&D, particularly in the development of novel oncology treatments targeting hematologic malignancies and solid tumors. Tipifarnib CAS NO 192185-72-1 is a key intermediate for researchers and manufacturers in the advanced pharmaceutical and biotechnology sectors.

Application

• Oncology Research: Primary application as a clinical-stage investigational drug for the treatment of various cancers, including HRAS-mutant head and neck squamous cell carcinoma (HNSCC), T-cell lymphomas, and leukemias.
• Farnesyltransferase Inhibition Studies: Used as a reference standard in biochemical and cellular assays to study the role of protein farnesylation in cell proliferation and survival pathways.
• Pharmaceutical Intermediate: Serves as a critical active pharmaceutical ingredient (API) or advanced intermediate in the synthesis of final drug formulations for clinical trials.
• Mechanism of Action Research: Employed in preclinical studies to elucidate the downstream effects of Ras pathway inhibition and to identify potential combination therapies.
• Reference Standard: Utilized in analytical laboratories for method development, validation, and quality control of related pharmaceutical products.

Basic Information

Product Name	Tipifarnib
CAS No.	192185-72-1
Molecular Formula	C27H31Cl2N3O4
Molecular Weight	532.46 g/mol
Synonyms	R115777; Zarnestra; (R)-6-[(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; 4-(3-Chlorophenyl)-1-methyl-6-[[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-2(1H)-quinolinone; Farnesyl Transferase Inhibitor R115777
EINECS	Contact for details

Quality Control

Our Tipifarnib is manufactured under strict quality management systems to ensure the highest standards of purity and consistency, suitable for research and development use. Each batch is accompanied by a comprehensive Certificate of Analysis (COA) detailing critical parameters such as assay, purity, and impurity profiles. We adhere to relevant industry guidelines to support our clients in pharmaceutical development. Certificates of Analysis (COA) are available upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider desiccants or inert atmosphere conditions.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Related Substances (HPLC)	Total impurities ≤2.0%
Single Maximum Impurity	≤0.5%
Water Content (KF)	≤1.0%
Residue on Ignition	≤0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.